Cloud-Clone launches CK antibody series for research and diagnostics

Cloud-Clone has introduced a Cytokeratin antibody portfolio built with in-house R&D and batch-level quality controls. The company says the lineup is designed to improve specificity, traceability and reproducibility for life-science and in-vitro diagnostic users.

Why it matters: - Cytokeratin antibodies are widely used in research and diagnostics, so batch consistency and specificity directly affect assay reliability and clinical precision. - Cloud-Clone is positioning its CK portfolio as an alternative to imported reagents that can be expensive, slow to arrive and inconsistent between lots. - The launch targets researchers, quality-control teams and diagnostic manufacturers that need reproducible staining and traceable data.

What happened: - Cloud-Clone launched a Cytokeratin antibody series built through full-chain in-house R&D and manufacturing. - The company says the portfolio is designed to match leading global suppliers on performance. - The release was announced in Houston, Texas, on Sept. 21, 2026. - Cloud-Clone said the CK line supports life-science research and in-vitro diagnostic use.

The details: - Cloud-Clone said every step, from antigen design and protein expression to animal immunization, antibody purification and labeling, is handled in-house. - The company uses a three-level quality-control system covering raw materials, production and finished products. - At the raw-material stage, each antigen batch undergoes sequencing analysis and purity verification to improve isoform-specific targeting. - At the production stage, semi-automated lines are used to reduce human error and keep batch performance consistent. - At the finished-product stage, each antibody batch is cross-validated across multiple tissue and cell samples. - Cloud-Clone said it maintains a proprietary information-management system that stores full test datasets and raw imaging records for each lot. - The CK panel covers low- and high-molecular-weight isoforms, plus pan-CK and isoform-specific targets. - The series includes CK7 and CK20 for adenocarcinoma primary-site identification. - The portfolio includes CK8 and CK18 for epithelial-origin studies, apoptosis monitoring and liver-related research. - The series includes CK19 for biliary and pancreatic duct epithelia, as well as tumor staging and prognosis research. - The portfolio includes CK1, CK10 and CK12 for stratified squamous epithelia and corneal epithelium. - Cloud-Clone said its CK antibodies are validated for WB, IHC, IF, ELISA and flow cytometry. - The company said it offers more than 27,000 ready-to-ship antibodies across 10 research areas, including oncology, immunology, neuroscience and cardiovascular science. - Cloud-Clone said each antibody can be conjugated with more than 30 labels, creating nearly one million antibody derivatives. - The company also said application-validation results and immunogen information are publicly available on its website. - Cloud-Clone offers custom antibody development, including FITC and PE labeling and epitope-specific antibody generation.

Between the lines: - The launch is as much about manufacturing credibility as it is about a product list. - By emphasizing source-level control, batch traceability and archived raw data, Cloud-Clone is trying to address common pain points in antibody procurement and validation. - The breadth of the catalog also signals that the CK series is part of a larger effort to compete on scale, not just on a single niche product.

What's next: - Cloud-Clone said it will keep expanding validated antibody resources and independent reagent innovation. - The company said it aims to support global scientific research and public-health objectives through broader access to high-performance reagents. - Large-scale inventory and technical support are intended to keep research and diagnostic projects moving without supply interruptions.

The bottom line: - Cloud-Clone is betting that in-house manufacturing, traceability and broad validation will help its CK antibodies stand out in a crowded reagent market.